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COVID-19 comorbidities, associated procoagulant extracellular
vesicles and venous thromboembolisms: a possible link with
ethnicity?
In view of numerous recent reports describing increased risks
of thrombosis in coronavirus disease 2019 (COVID-19)
amongst certain ethnicities in which co-morbidities are more
prevalent, besides the identified risk factors, procoagulant
plasma extracellular vesicles have not been considered. Sev-
eral comorbidities predict mortality in patients with COVID-
19, some of which are more prevalent in Black, Asian and
Minority Ethnic (BAME) groups. In a meta-analysis of seven
studies (1,576 infected patients) the co-morbidities included
hypertension (211%), diabetes (97%), cardiovascular disease
(CVD), (84%) and respiratory system disease (15%).1 Of
the critically ill COVID-19 patients with these co-morbidities
and an associated hyperinflammatory state admitted to
intensive care units (ICUs), up to 31% suffered thrombotic
episodes (even with thromboprophylaxis), in particular,
venous thromboembolisms (VTE),2 one of the important
sequelae of COVID-19.
Extracellular vesicles (EVs) are nano-sized, membrane-
bound vesicles released from cells that carry nucleic acids and
proteins, and which mediate intercellular communication. In
COVID-19-associated co-morbidities, including diabetes,
CVD and risk factors such as hypertension, elevated angioten-
sin II (Ang II) and obesity, levels of circulating EVs are
raised.3-6 Increased EVs, especially from injured or TNF-a-
stimulated endothelial cells (EC) carrying tissue factor (TF+),
or from platelets exposing phosphatidylserine (PS+), are
known to be procoagulant and to cause VTE.7 Levels of EVs
also correlate with von Willebrand Factor (vWF), a marker of
EC damage and dysfunction.8 This endothelial injury is due
to Ang II-mediated superoxide damage and hypoxia-mediated
oxidative stress as well as severe acute respiratory syndrome
coronavirus (SARS-CoV-2) binding to angiotensin-converting
enzyme 2 (ACE2) on ECs and ensuing complement-mediated
inflammation9 (Fig 1A,B). Previously, endothelial cell-derived
medium EV (EC-mEV) levels were found to be associated
with stroke.10 More recently, CD31+ and CD144+ EC-derived
mEVs, phenotypes reflecting apoptosis and structurally dam-
aged endothelium, were found to relate to risk factors for
CVD and, thus, increased the risk of VTE, especially raised
triglycerides, hypertension and metabolic syndrome.4
Could it therefore, be that raised circulating EVs with
modulated cargo in certain comorbidity groups, in addition
to infection with SARS-CoV-2, renders COVID-19 patients
particularly susceptible to VTE? If so, EVs could be used as
biomarkers in COVID-19. A TF+-EV procoagulant activity
assay, for example, based on fibrin formation, previously
used in monitoring the risk of VTE in cancer patients,
should be tried in COVID-19.
It was recently reported that higher rates of death from
COVID-19 in the UK were found in BAME patients.11 This
study used the Standardized Mortality Ratio (SMR) to calcu-
late the risk of death (adjusted for age and region), for
BAME patients compared to the general population. The
adjusted ethnic-specific SMRs were as follows: 329 (Pak-
istani), 324 (Black African), 241 (Bangladeshi), 221 (Black
Caribbean) and 17 (Indian). In a UK study by Valabhji
et al. (in preprint: https://www.england.nhs.uk/wp-content/
uploads/2020/05/Valabhji-COVID-19-and-Diabetes-Paper-2-
Full-Manuscript.pdf), assessing the risk people with diabetes
face of dying of COVID-19, 418 COVID-19-related deaths
from 265 090 people with Type 1 diabetes (T1D) and 9,377
deaths from 2 889 210 people with T2D were analysed. It
was found that there was a higher mortality risk of COVID-
19-related death for people of Asian or Black ethnicities with
diabetes. Specifically, for T1D the adjusted hazard ratio, was
179 and 168 for the Asian and Black groups respectively,
compared to the White group. For T2D the hazard ratio was
109 for Asian and 163 for people of Black ethnicity, com-
pared to the White group. In the International Severe Acute
Respiratory and Emerging Infections Consortium/UK Clinical
Characterisation Protocol (ISARIC/CCP-UK) study, looking
at 34 968 patients admitted to hospitals in England, Scotland
and Wales, South Asians with COVID-19 were 20% more
likely to die than Whites.12 Compared to the White group,
South Asians had the highest hazard ratio of death (119)
followed by Black patients (105) and around 40% of the
South Asian and Black patients had T1D or T2D. This pre-
existing co-morbidity accounted particularly for the excess
mortality observed amongst the South Asians.
If plasma EV levels are raised, and cargo modified in co-
morbidities associated with COVID-19, such as diabetes,
account for excess deaths in BAME patients, could EVs be
playing a role and might there be a connection to ethnicity?
In the United States, African Americans (AA) show a dispro-
portionately high co-mborbidity-associated death rate from
COVID-19, compared to White Americans (WA).13 Interest-
ingly, in a study looking firstly at the concentration and
mean/modal sizes of circulating plasma EVs in AA and WA,
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regardless of gender, no ethnic difference was found.14 How-
ever, assessing EV protein content involved in insulin sig-
nalling, the study found lower levels of phospho-AKT
(pAKT) in AAs compared to WAs, which is associated with
impaired insulin signalling, insulin resistance and an
increased risk of VTE. Importantly, considering phosphory-
lated insulin signalling proteins, shown previously by the
same study to be in EVs and related to diabetes mellitus,2,3
the association of these EV proteins with clinical mortality
risk markers, such as serum creatinine, lactate dehydroge-
nase, homeostatic model assessment of b-cell function, serum
alkaline phosphatase and pulse pressure, did seem to depend
on ethnicity.
The connection between EV cargo, mortality markers and
race may be of considerable importance because of the cur-
rent knowledge gap in susceptibility for COVID-19 amongst
BAME patients. We know that EVs play a role in T2D3 and
CVD,4 and may thus constitute important risk factors lead-
ing to VTE in COVID-19 patients. It is already known that
proteins such as vWF, which contributing to VTE, show an
association with ethnicity.15 However, given that certain EV
proteins and their relationship with clinical mortality mark-
ers may also vary according to ethnicity (see Fig 1A,B), and
contribute to clinical outcomes, now might be an opportune
time to begin to use EV carrying molecules as markers of
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S6RP, S6 ribosomal protein
AKT, protein kinase B
70S6K, P70 S6 kinase
GSK3β, Glycogen synthase kinase 3β
IGF-1R, Insulin-like growth factor 1 receptor
IRS1, Insulin receptor substrate 1 
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Fig 1. (A and B) Extracellular vesicles (EVs) and coagulopathy in COVID-19 and a possible link with ethnicity. SARS-CoV-2 infection activates
the complement and formation of membrane attack complex (MAC, C5b-9). The resulting Ca2+ influx through deposited C5b-9 and by the
SARS-CoV-2 E-protein Ca2+ channel from Endoplasmic reticulum-Golgi intermediate compartment/endoplasmic reticulum (ERGIC/ER), leads to
Ca2+-mediated EV release. Circulating EVs carrying phosphorylated insulin signalling proteins and related to diabetes mellitus, an important
comorbidity in COVID-19, are associated with clinical mortality risk markers linked to ethnicity. (A) In severe COVID-19, in particular in ethnic-
ities with increased comorbidities such as diabetes, and associated circulating EV levels, EVs with their known role in coagulopathy could play an
important role in COVID-19-related deaths through VTE. BAME. Black Asian and Minority Ethnic groups.
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